Haematologic Malignancies
The North Estonia Medical Centre Foundation is involved in clinical research on multiple myeloma, with interest in treatment strategies that deepen response in newly treated, transplant-eligible patients and improve minimal residual disease negativity and complete response outcomes.
- Multiple myeloma
- T-cell redirecting therapies
- Bispecific antibodies
- Minimal residual disease
Its research activity in this area reflects a focus on immune-based approaches for deeper disease control in plasma cell disorders.
Melanoma and Skin Cancer
The sponsor also supports studies in cutaneous malignant melanoma, particularly in patients with high-risk disease after surgery, where the therapeutic interest centres on adjuvant immunotherapy and treatment duration.
- Cutaneous malignant melanoma
- Adjuvant immunotherapy
- High-risk melanoma
- Post-surgical treatment
This area of research addresses stage IIb-c, III and IV melanoma in the setting of recurrence prevention and long-term disease management.
Immune-Based Oncology
Across its funded trials, the centre shows a strong interest in immuno-oncology, including therapies designed to direct or enhance T-cell activity against cancer cells in both haematological and solid tumours.
- Immuno-oncology
- T-cell engagement
- Antitumour immune response
- Oncology immunotherapy
This therapeutic domain links the sponsor’s work in myeloma and melanoma through immune-mediated treatment strategies.
